CN105585559A - 2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 - Google Patents
2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 Download PDFInfo
- Publication number
- CN105585559A CN105585559A CN201610052932.XA CN201610052932A CN105585559A CN 105585559 A CN105585559 A CN 105585559A CN 201610052932 A CN201610052932 A CN 201610052932A CN 105585559 A CN105585559 A CN 105585559A
- Authority
- CN
- China
- Prior art keywords
- methyl
- derivative
- indol
- methoxyl group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- MOXBKVYQWGMIPR-UHFFFAOYSA-N 2-(1H-indol-3-ylmethoxymethyl)-1H-benzimidazole Chemical class N1C=C(C2=CC=CC=C12)COCC1=NC2=C(N1)C=CC=C2 MOXBKVYQWGMIPR-UHFFFAOYSA-N 0.000 title abstract 3
- -1 -CCl3 Chemical group 0.000 claims abstract description 43
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 24
- IVYPNXXAYMYVSP-UHFFFAOYSA-N indole-3-methanol Chemical compound C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 6
- 239000003054 catalyst Substances 0.000 claims abstract description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 239000000376 reactant Substances 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 3
- 239000000460 chlorine Substances 0.000 claims abstract description 3
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 3
- 239000011630 iodine Substances 0.000 claims abstract description 3
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 6
- 235000002279 indole-3-carbinol Nutrition 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 150000002012 dioxanes Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- WIHIUTUAHOZVLE-UHFFFAOYSA-N 1,3-diethoxypropan-2-ol Chemical compound CCOCC(O)COCC WIHIUTUAHOZVLE-UHFFFAOYSA-N 0.000 claims description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 229940072033 potash Drugs 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 4
- 230000035484 reaction time Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 4
- IAJLTMBBAVVMQO-UHFFFAOYSA-N 1h-benzimidazol-2-ylmethanol Chemical compound C1=CC=C2NC(CO)=NC2=C1 IAJLTMBBAVVMQO-UHFFFAOYSA-N 0.000 abstract 2
- SPMLMLQATWNZEE-UHFFFAOYSA-N 2-(chloromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(CCl)=NC2=C1 SPMLMLQATWNZEE-UHFFFAOYSA-N 0.000 abstract 2
- RTJHMNHFKRGENK-UHFFFAOYSA-N 3-(chloromethyl)-1h-indole Chemical compound C1=CC=C2C(CCl)=CNC2=C1 RTJHMNHFKRGENK-UHFFFAOYSA-N 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 238000005580 one pot reaction Methods 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 235000011181 potassium carbonates Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000010792 warming Methods 0.000 description 9
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 2
- 229950003968 motesanib Drugs 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种由下述通式表示的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物：其中，式中取代基R1、R7可以为-H，-CH3，-CH2CH3，-CHCH＝CH2，-CH2Ph，-COCH3，p-CH3-C6H4-SO2-；R2、R3、R4、R5、R6、R8、R9、R10、R11可以为-H，-CH3，-CH2CH3，-CHCH＝CH2，-CH2Ph，-COCH3，-CF3，-CCl3，-CN，-NHCH3，-NO2，-OCH3，-CH2NH2，-COOCH3，-CONHCH3。本发明方法是以吲哚-3-甲醇及其衍生物和2-卤甲基苯并咪唑及其衍生物或以3-卤甲基吲哚及其衍生物和苯并咪唑-2-甲醇及其衍生物为反应物，在适当的溶剂和催化剂的条件下，经一步反应生成2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物。该系列化合物的制备如下：
Description
技术领域
本发明涉及药物化学技术领域，具体涉及到2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物及其制备方法。
背景技术
吲哚和苯并咪唑类化合物由于具有天然化合物的活性而在医药、农药、染料等领域应用广泛，为此也成为杂环化合物研究的热点，前景发展十分广阔。许多研究还表明，含有吲哚和苯并咪唑结构片段的化合物具有良好的抗肿瘤活性，如吲哚衍生物舒尼替尼(Sunitinib)、莫替沙尼(Motesanib)和苯并咪唑衍生物多韦替尼(Dovitinib)等都是目前已经上市的有效的抗癌药物。
文献(ShaukatA,MirzaHM,AnsariAH,etal.Benzimidazolederivatives:synthesis,leishmanicidaleffectiveness,andmoleculardockingstudies[J].MedicinalChemistryResearch,2013,22(8):3606-3620.)报道了一类具有较高的抗肿瘤活性的含吲哚-苯并咪唑结构化合物的合成，但是迄今为止，吲哚-苯并咪唑类化合物种类极少，醚键连接的吲哚-苯并咪唑衍生物及其制备方法在国内外文献未见报道。
舒尼替尼(Sunitinib)、莫替沙尼(Motesanib)和多韦替尼(Dovitinib)的结构
发明内容
本发明所要解决的技术问题是提供一种2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物及其制备方法。本发明采用的技术方案如下：
一种由下述通式表示的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物：
其中，式中取代基R1、R7可以为氢，甲基，乙基，丙基，烯丙基，苄基，甲酰基，乙酰基，甲磺酰基，苯磺酰基，对甲苯磺酰基；R2、R3、R4、R5、R6、R8、R9、R10、R11可以为氢，甲基，乙基，丙基，烯丙基，苄基，磺酰基，苯磺酰基，对甲苯磺酰基，氟代甲基，氟代乙基，氟代丙基，氯代甲基，氯代乙基，氯代丙基，氰基，甲氨基，二甲氨基，乙胺基，二乙胺基，硝基，磺氨基，甲氧基，氨甲基，乙酰基，甲氧羰基，氨基甲酰基，N-甲基氨基甲酰基。
本发明方法是以吲哚-3-甲醇及其衍生物和2-卤甲基苯并咪唑及其衍生物或以3-卤甲基吲哚及其衍生物和苯并咪唑-2-甲醇及其衍生物为反应物；四氢呋喃、硝基甲烷、丙酮、二恶烷、N，N-二甲基甲酰胺、乙腈等为溶剂；碳酸钾、碳酸钠、三乙胺、吡啶等为催化剂，一步反应生成2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物。
根据本发明，该系列化合物的制备方法如下：
其中，式中的X基团为氯、溴或碘。
具体实施方式
现将对本发明的具有代表性的实施方案进行举例说明，仅仅是示例性的说明，通过下述实施例将有助于理解本发明，但所举实例并不限制本发明的范围。
实施例1：向50ml三口瓶中加入1.19g1-苄基吲哚-3-甲醇，10ml四氢呋喃，开启搅拌，室温下缓慢滴加含0.83g2-氯甲基苯并咪唑的四氢呋喃溶液10ml，升温至60℃，加入1.0g碳酸钾粉末，反应4h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得1.15g2-(((1-苄基-1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑，产率62.7％。
实施例2：向50ml三口瓶中加入1.19g1-苄基吲哚-3-甲醇，10ml二恶烷，开启搅拌，室温下缓慢滴加含1.06g2-氯甲基-5-硝基苯并咪唑的二恶烷溶液10ml，升温至80℃，加入碳酸钾粉末1.0g，反应4h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得1.11g2-(((1-苄基-1H-吲哚-3-基)氧基)甲基)-5-硝基-1H-苯并咪唑，产率53.9％。
实施例3：向50ml三口瓶中加入0.94g1-烯丙基吲哚-3-甲醇，10mlN,N-二甲基甲酰胺，开启搅拌，室温下缓慢滴加含0.82g2-氯甲基-5-甲基苯并咪唑的N,N-二甲基甲酰胺溶液10ml，升温至100℃，加入1.0g碳酸钾粉末，反应5h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得1.15g2-(((1-烯丙基-1H-吲哚-3-基)甲氧基)甲基)-5-甲基-1H-苯并咪唑，产率69.5％。
实施例4：向50ml三口瓶中加入0.97g5-硝基吲哚-3-甲醇，10ml丙酮，开启搅拌，室温下缓慢滴加含1.06g2-氯甲基苯并咪唑的丙酮溶液10ml，升温至55℃，加入1.0g碳酸钾粉末，反应4h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得1.03g2-(((5-硝基-1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑，产率64.0％。
实施例5：向50ml三口瓶中加入0.81g4-甲基吲哚-3-甲醇，10ml四氢呋喃，开启搅拌，室温下缓慢滴加含0.98g2-氯甲基-5-甲氧基苯并咪唑的四氢呋喃溶液10ml，升温至60℃，加入1.0g碳酸钾粉末，回流反应6h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得0.84g5-甲氧基-2-(((4-甲基-1H-吲哚-3-基)氧基)甲基)-1H-苯并咪唑，产率52.3％。
实施例6：向50ml三口瓶中加入1.05g1-甲基-3-氯甲基-5-甲氧基吲哚，10ml丙酮，开启搅拌，室温下缓慢滴加含0.74g苯并咪唑-2-甲醇的丙酮溶液10ml，升温至60℃，加入1.0g碳酸钾粉末，反应5h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得0.96g2-(((5-甲氧基-1-甲基-1H-吲哚-3-基)氧基)甲基)-1H-苯并咪唑，产率59.8％。
实施例7：向50ml三口瓶中加入1.35g1-苄基-3-氯甲基-4-甲基吲哚，10ml硝基甲烷，开启搅拌，室温下缓慢滴加含0.74g苯并咪唑-2-甲醇的硝基甲烷溶液10ml，升温至80℃，加入1.0g碳酸钾粉末，反应4h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得1.25g2-(((1-苄基-4-甲基-1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑，产率65.6％。
实施例8：向50ml三口瓶中加入1.35g1-苄基-3-氯甲基-7-甲基吲哚，10ml硝基甲烷，开启搅拌，室温下缓慢滴加含0.97g5-硝基苯并咪唑-2-甲醇的硝基甲烷溶液10ml，升温至80℃，加入1.0g碳酸钾粉末，反应4h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得1.35g2-(((1-苄基-7-甲基-1H-吲哚-3-基)甲氧基)甲基)-5-硝基-1H-苯并咪唑，产率63.4％。
实施例9：向50ml三口瓶中加入1.06g3-氯甲基-7-硝基吲哚，10ml乙腈，开启搅拌，室温下缓慢滴加含0.81g7-甲基苯并咪唑-2-甲醇的乙腈溶液10ml，升温至60℃，加入1.0g碳酸钾粉末，反应7h。待反应完毕，过滤，滤液浓缩，经柱色谱层析方法分离得1.14g7-甲基-2-(((7-硝基-1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑，产率53.5％。
Claims (11)
1.一种由下述通式表示的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物：
其中，式中取代基R1、R7可以为氢，甲基，乙基，丙基，烯丙基，苄基，甲酰基，乙酰基，甲磺酰基，苯磺酰基，对甲苯磺酰基；R2、R3、R4、R5、R6、R8、R9、R10、R11可以为氢，甲基，乙基，丙基，烯丙基，苄基，磺酰基，苯磺酰基，对甲苯磺酰基，氟代甲基，氟代乙基，氟代丙基，氯代甲基，氯代乙基，氯代丙基，氰基，甲氨基，二甲氨基，乙胺基，二乙胺基，硝基，磺氨基，甲氧基，氨甲基，乙酰基，甲氧羰基，氨基甲酰基，N-甲基氨基甲酰基。
2.根据权利要求1中所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物，其制备方法的特征在于：
在催化剂催化下，反应物吲哚-3-甲醇及其衍生物和2-卤甲基苯并咪唑及其衍生物在一定温度的溶剂中反应生成2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物，或者反应物3-卤甲基吲哚及其衍生物和苯并咪唑-2-甲醇及其衍生物在一定温度的溶剂中反应生成2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物。
3.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，式中的X基团为氯、溴或碘。
4.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，反应所用的溶剂可以为四氢呋喃，硝基甲烷，丙酮，二恶烷，N,N-二甲基甲酰胺，乙腈。
5.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，反应所用的催化剂可以为碳酸钾，碳酸钠，三乙胺，吡啶。
6.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，吲哚-3-甲醇及其衍生物与2-卤甲基苯并咪唑及其衍生物的物料摩尔比为1：0.5～10。
7.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，吲哚-3-甲醇及其衍生物与催化剂的物料摩尔比为1：1～40。
8.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，3-卤甲基吲哚及其衍生物与苯并咪唑-2-甲醇及其衍生物的物料摩尔比为1：0.5～10。
9.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，3-卤甲基吲哚及其衍生物与与催化剂的物料摩尔比为1：1～40。
10.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，反应时间为2至12小时。
11.根据权利要求2所述的2-(((1H-吲哚-3-基)甲氧基)甲基)-1H-苯并咪唑类衍生物的制备方法，其特征在于，反应温度为10至100℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610052932.XA CN105585559A (zh) | 2016-01-26 | 2016-01-26 | 2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610052932.XA CN105585559A (zh) | 2016-01-26 | 2016-01-26 | 2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105585559A true CN105585559A (zh) | 2016-05-18 |
Family
ID=55925500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610052932.XA Pending CN105585559A (zh) | 2016-01-26 | 2016-01-26 | 2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105585559A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106008472A (zh) * | 2016-06-14 | 2016-10-12 | 青岛科技大学 | 脲基连接的吲哚-苯并咪唑衍生物及其合成 |
| CN107021959A (zh) * | 2017-05-02 | 2017-08-08 | 青岛科技大学 | 一类新型吲哚衍生物及其体外抗肿瘤活性 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1938281A (zh) * | 2004-03-08 | 2007-03-28 | 惠氏公司 | 离子通道调节剂 |
| CN104387371A (zh) * | 2014-10-20 | 2015-03-04 | 青岛科技大学 | 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 |
-
2016
- 2016-01-26 CN CN201610052932.XA patent/CN105585559A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1938281A (zh) * | 2004-03-08 | 2007-03-28 | 惠氏公司 | 离子通道调节剂 |
| CN104387371A (zh) * | 2014-10-20 | 2015-03-04 | 青岛科技大学 | 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成 |
Non-Patent Citations (1)
| Title |
|---|
| AWAIS SHAUKAT等: "Benzimidazole derivatives: synthesis, leishmanicidal effectiveness,and molecular docking studies", 《MEDICINAL CHEMISTRY RESEARCH》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106008472A (zh) * | 2016-06-14 | 2016-10-12 | 青岛科技大学 | 脲基连接的吲哚-苯并咪唑衍生物及其合成 |
| CN107021959A (zh) * | 2017-05-02 | 2017-08-08 | 青岛科技大学 | 一类新型吲哚衍生物及其体外抗肿瘤活性 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Enantioselective copper-catalyzed [3+ 3] cycloaddition of azomethine ylides with azomethine imines | |
| Lygin et al. | Isocyanides in the synthesis of nitrogen heterocycles | |
| FI63757B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara kinoxalin- och kinazolinderivat | |
| Vessally et al. | Chemical fixation of CO2 with aniline derivatives: A new avenue to the synthesis of functionalized azole compounds (A review) | |
| Mahajan et al. | Enantioselective synthesis of pyrazolone α-aminonitrile derivatives via an organocatalytic Strecker reaction | |
| JPS6172A (ja) | 新規アミノアルキル複素環式化合物 | |
| CN104302287B (zh) | 作为蛋白质激酶抑制剂的吲哚啉‑2‑酮衍生物 | |
| Jing et al. | Lanthanide-catalyzed cyclocarbonylation and cyclothiocarbonylation: a facile synthesis of benzannulated 1, 3-diheteroatom five-and six-membered heterocycles | |
| Bharti et al. | Multicomponent synthesis of diverse pyrano-fused benzophenazines using bifunctional thiourea-based organocatalyst in aqueous medium | |
| Seki | An efficient c–h arylation of a 5-phenyl-1h-tetrazole derivative: A practical synthesis of an angiotensin II receptor blocker | |
| Li et al. | Enantioselective Synthesis of N‐Phenyl‐dihydropyrano [2, 3‐c] pyrazoles via Cascade Michael Addition/Thorpe‐Ziegler Type Cyclization Catalyzed by a Chiral Squaramide | |
| CN105585559A (zh) | 2-(((1h-吲哚-3-基)甲氧基)甲基)-1h-苯并咪唑类衍生物及其制备 | |
| Zhang et al. | A unique one-pot reaction via CC cleavage from aminomethylene benzimidazoles to access benzimidazolones with wide potentiality | |
| Bollikolla et al. | Advances in synthesis and biological activities of benzotriazole analogues: A micro review | |
| WO2005066161A1 (en) | Tricyclic steroid hormone nuclear receptor modulators | |
| Wang et al. | Imidazobenzothiazine and primidobenzothiazine derivatives synthesis via an aliphatic SN2 substitution/Cu (I) catalyzed Ullmann coupling cascade process | |
| CN112574112B (zh) | 一种氧化合成n-取代2h-吲唑类化合物的方法 | |
| CN106674097A (zh) | 一种瑞戈非尼杂质的制备方法 | |
| JP2009533441A (ja) | ５‐ヒドロキシトリプタミン‐６リガンドとしての置換ジヒドロ［１，４］オキサジノ［２，３，４‐ｈｉ］インダゾール誘導体 | |
| Khattab et al. | Different synthetic routes to 4-(1 H-benzo [d] imidazol-2-yl) aniline | |
| US9328079B2 (en) | Process for producing optically active amine | |
| CN110526853B (zh) | 3,3-二取代-2-吲哚酮衍生物及其制备方法 | |
| CN104610267A (zh) | 无催化条件下高效的合成6-烷基吡唑并[1,5-c]喹唑啉骨架化合物的方法 | |
| GB2131020A (en) | Bis(nitro-1-imidazolyl alkylamine) platinum complexes useful in radiotherapy or chemotherapy | |
| Zhang et al. | Facile one-pot synthesis of polysubstituted quinolines under solvent-free conditions using sulfamic acid as a reusable catalyst |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160518 |
|
| WD01 | Invention patent application deemed withdrawn after publication |